Delivery Order SPE2DB24D1205-SPE2DB24FCSNN

Award Date 7/8/24
Potential Completion Date 7/29/24
Potential Value $13K
Ultimate Awardee
Not listed
Federal Contract Vehicle
Set-Aside Type
No Set-Aside Used
Extent Competed
Full and Open Competition
Major Defense Program
Not listed
Pricing Type
Firm Fixed Price
Place of Performance
Conshohocken, PA 19428, USA
Solicitation Procedures
Negotiated Proposal / Quote
Number Of Offers Received
Not listed
Legislative Mandate
Not listed
National Interest Action
Not listed
Research Type
Not listed
Primary Consortia Member
Not listed
Similar Awards
This is a federal contract award from the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The $41,540.91 firm-fixed-price delivery order is for VYNDAMAX 61 MG CAPSULE UD 30S, a pharmaceutical product. The contract has an ultimate completion date of June 17, 2025. AmerisourceBergen Drug Corp holds a significant $999,999,999.00 Indefinite Delivery Contract (IDC) with the DLA Troop Support Medical, which provides a...
This federal contract award was issued by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The $12,960.30 Firm Fixed Price Delivery Order contract is for the supply of VYNDAMAX 61 MG CAPSULE UD 30S, a pharmaceutical product. The contract has an ultimate completion date of July 8, 2024 and was awarded on June 13, 2024. The award is not associated with a set-aside program. AmerisourceBergen holds a $999,999,999...
This federal contract award was issued by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The $13,408.24 firm fixed-price delivery order is for the supply of VYNDAMAX 61 MG CAPSULE UD 30S, a pharmaceutical product. The contract has a period of performance through February 18, 2025 and does not have a set-aside designation, indicating open competition. AmerisourceBergen holds a $999,999,999 Indefinite...
This federal contract award was made by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The $24,690.70 firm fixed-price delivery order is for the supply of VYNDAMAX 61 MG Capsules, with a completion date of July 27, 2022. The contract is not designated as a set-aside. AmerisourceBergen holds a significant $999,999,999 Indefinite Delivery Contract (IDC) with the DLA Troop Support Medical, which serves as a...
This federal contract award to AmerisourceBergen Drug Corp, a major pharmaceutical distributor, is for the delivery of the drug VYNDAMAX 61 MG CAPSULE UD 30S. The $12,960.30 firm fixed-price delivery order was awarded by the Defense Logistics Agency (DLA) on June 25, 2024, with a completion date of July 17, 2024. The contract does not have a set-aside designation, indicating open competition. AmerisourceBergen holds a significant $999,999,999 Indefinite Delivery Contract (IDC) with the DLA Troop...
This federal contract award was issued by the Defense Logistics Agency (DLA) Troop Support Medical to Amerisourcebergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The $13,408.24 firm fixed-price delivery order is for the supply of VYNDAMAX 61 MG CAPSULE UD 30S, a specialty pharmaceutical product. The contract has an ultimate completion date of December 13, 2024 and was awarded on November 21, 2024. Amerisourcebergen holds a significant $999,999,999...
This federal contract award, valued at $13,408.24, was issued by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The contract is for the delivery of VYNDAMAX 61 MG CAPSULE UD 30S, a specialty pharmaceutical product, with a period of performance through January 22, 2025. The contract is a firm-fixed-price Delivery Order and does not have a set-aside designation. In addition to this specific contract,...
This is a federal contract award from the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The contract, valued at $13,846.97, is for the delivery of VYNDAMAX 61 MG CAPSULE UD 30S, a pharmaceutical product. The contract is a Firm Fixed Price Delivery Order with a period of performance through May 2, 2025. The contract has no set-aside designation, indicating open competition. AmerisourceBergen holds a larger...
This federal contract award was issued by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The $13,408.24 firm-fixed-price delivery order is for VYNDAMAX 61 MG CAPSULE UD 30S, with a performance period ending on March 21, 2025. The contract does not have a set-aside designation, indicating it was competed openly. AmerisourceBergen holds a $999,999,999 Indefinite Delivery Contract (IDC) with the DLA Troop...
This federal contract award, valued at $13,846.97, was issued by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The award is for the delivery of VYNDAMAX 61 MG CAPSULE UD 30S, a pharmaceutical product, with a period of performance through May 29, 2025. The contract is a Firm Fixed Price Delivery Order, with no set-aside designation, indicating open competition. AmerisourceBergen Drug Corp holds a...
  • SPE2DB24D1205
    Indefinite Delivery Contract
  • SPE2DB24D1205-SPE2DB24FCSNN
    Delivery Order

This federal contract award was issued by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The $12,960.30 firm-fixed-price delivery order is for the VYNDAMAX 61 MG CAPSULE UD 30S medical product. The contract has an ultimate completion date of July 29, 2024.

AmerisourceBergen holds a significant $999,999,999 Indefinite Delivery Contract (IDC) with the DLA Troop Support Medical through November 2026, which serves as a primary vehicle for providing a comprehensive range of pharmaceutical products and medical supplies to support military healthcare programs globally. The company also maintains a separate $750,000 IDC with the Department of Justice Federal Bureau of Investigation through May 2024, covering similar medical products and prescription drugs.

This federal contract award was not designated with any set-aside requirements, indicating open competition. The contract supports the DLA's mission of providing critical pharmaceutical and medical commodities to military treatment facilities, veterans' healthcare programs, and other federal medical institutions.

Generated 5/17/25, 10:01 AM